Stuart Holden Net Worth

Stuart Holden biography

Dr. Stuart Holden M.D. is Independent Director of the Company. Dr. Holden has been the Chairman of ProQuest Investments’ Scientific Advisory Board since it was founded in 1998. Since May 2014, Dr. Holden has served as a member of the UCLA faculty as a Health Sciences Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology, in the Department of Urology at the UCLA David Geffen School of Medicine and Associate Director of the UCLA Institute of Urologic Oncology. Dr. Holden has worked in the field of prostate cancer for more than 36 years. Dr. Holden also serves as Medical Director of the Prostate Cancer Foundation since the foundation’s inception in 1993. Dr. Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. Dr. Holden has served as a member of the board of directors of Telormedix SA from 2008 to 2017 and served as a member of the board of directors of Acurian, Inc. from 1999 through 2014. Dr. Holden also served on the Board of the American College of Medical Informatics from 1999 through 2006 and is currently on the board of Clarus Therapeutics. In addition, he was a founding partner at Tower Urology in Los Angeles. Dr. Holden received a B.S. degree from the University of Wisconsin-Madison and completed his medical degree and received his surgical training at Weill Cornell Medical College and the New York Hospital-Cornell University Medical College. He completed his urology residency at Emory University School of Medicine and fellowships in urology and developmental genetics at Memorial Sloan-Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society. Dr. Holden was appointed to serve on our board by ProQuest Investments IV, L.P., one of our shareholders, pursuant to rights granted to such shareholder under our articles of association as in effect prior to our initial public offering. Our Board believes Dr.

What is the salary of Stuart Holden?

As the Independent Director of UroGen Pharma Ltd, the total compensation of Stuart Holden at UroGen Pharma Ltd is $320,198. There are 9 executives at UroGen Pharma Ltd getting paid more, with Elizabeth Barrett having the highest compensation of $25,900,800.

How old is Stuart Holden?

Stuart Holden is 77, he's been the Independent Director of UroGen Pharma Ltd since 2015. There are no older and 15 younger executives at UroGen Pharma Ltd.

What's Stuart Holden's mailing address?

Stuart's mailing address filed with the SEC is 400 ALEXANDER PARK DRIVE, , PRINCETON, NJ, 08540.

Insiders trading at UroGen Pharma Ltd

Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun, and Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.

What does UroGen Pharma Ltd do?

urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.

UroGen Pharma Ltd executives and stock owners

UroGen Pharma Ltd executives and other stock owners filed with the SEC include:

• Elizabeth Barrett,
  President, Chief Executive Officer, Director
• Elizabeth A. Barrett,
  Pres, CEO & Director
• Mark Schoenberg,
  Chief Medical Officer
• Ron Bentsur,
  Advisor
• Dr. Mark P. Schoenberg,
  Chief Medical Officer
• Arie Belldegrun,
  Independent Chairman of the Board
• Jason Drew Smith,
  Gen. Counsel & Chief Compliance Officer
• Cynthia Butitta,
  Independent Director
• Kathryn Falberg,
  Independent Director
• Stuart Holden,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Fred Cohen,
  Independent Director
• Shawn Tomasello,
  Independent Director
• Molly Henderson CPA, MBA,
  Chief Financial Officer
• Elyse Seltzer,
  Chief Development Officer
• Polly Murphy,
  Chief Business Officer
• Jeff Bova,
  Chief Commercial Officer
• Jason Smith,
  Chief Compliance Officer, General Counsel
• Jim Ottinger,
  Executive Vice President, Regulatory Affairs and Quality
• Marina Konorty,
  Executive Vice President, Research & Development and Technical Operations
• Molly Henderson,
  Chief Financial Officer, Principal Accounting Officer
• James Ottinger R.ph.,
  Exec. VP of Regulatory Affairs & Quality
• Jeffrey Bova M.B.A.,
  Chief Commercial Officer
• Dr. Sari Prutchi-Sagiv Ph.D.,
  Marketing Director
• Eric Van Zanten,
  Sr. Director of Communications
• Jason Smith,
  Gen. Counsel & Chief Compliance Officer
• Sara Blum Sherman,
  Sr. Director of Investor Relations
• James A. Jr. Robinson,
  Director
• Investments Iv, L.P.Pro Que...,
  
• Stephen Mullennix,
  Chief Operating Officer
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Leana Wen,
  Director
• Dong Kim,
  Chief Financial Officer
• Daniel George Wildman,
  Director